Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
about
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsComparative effects of 4-phenyl-3-butenoic acid and vorinostat on cell growth and signalingInvolvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma.The Histone Deacetylase Inhibitor Trichostatin A Sensitizes Human Renal Carcinoma Cells to TRAIL-Induced Apoptosis through Down-Regulation of c-FLIPL.A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastomaComplex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.Development of histone deacetylase inhibitors for cancer treatment.Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitorsThe HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.Immunocombination therapy for high-risk neuroblastoma.Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.Targeting of epigenetic regulators in neuroblastoma.The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction
P2860
Q28391040-1FE3CE32-D878-4DF0-A0B4-5D5DE1DFC6F7Q28392529-F5860377-704C-42F8-9CC7-EDA0B945FFE0Q34391785-F6510E3D-0083-46FC-861E-354284717DC6Q34865077-AF4C9D4E-53CD-44F4-918F-FE0E9B05E679Q35200982-1DA399AB-CAAC-4C10-9EF6-944327DC6012Q36015007-1EDBA681-924B-4F4C-B790-23E2A3CBF163Q36290436-E8B9FBEF-0455-46F0-8D21-92AF420B1B7DQ36742203-DBA96386-2856-4D20-BAD8-F12B12AF39E9Q36788512-50AAA66D-A2D0-494C-9631-69ACD8B7F61CQ37011621-AE809A51-C940-474E-94A5-6B6B2E6ECE49Q37212017-F5CEDB38-C5D5-4905-9BD6-762E29EBC104Q37991024-8AD1DE1B-A156-4C58-AF9F-D17E6A66E24EQ39400148-19F53229-039E-40FE-A0B0-7712FFE00F8DQ52560224-BCDAA4B8-D852-4F05-8E35-E6D82B1E187BQ59132751-34CC2F4A-1E78-4A09-B7E7-34992998FA04
P2860
Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Histone deacetylase inhibitors ...... anti-apoptotic proteins ratio.
@ast
Histone deacetylase inhibitors ...... anti-apoptotic proteins ratio.
@en
type
label
Histone deacetylase inhibitors ...... anti-apoptotic proteins ratio.
@ast
Histone deacetylase inhibitors ...... anti-apoptotic proteins ratio.
@en
prefLabel
Histone deacetylase inhibitors ...... anti-apoptotic proteins ratio.
@ast
Histone deacetylase inhibitors ...... anti-apoptotic proteins ratio.
@en
P2093
P2860
P356
P1433
P1476
Histone deacetylase inhibitors ...... anti-apoptotic proteins ratio
@en
P2093
Jean-Marc Joseph
Katia Balmas Bourloud
Katya Auderset
Marjorie Flahaut
Nicole Gross
Roland Meier
P2860
P2888
P356
10.1186/1471-2407-6-214
P407
P577
2006-08-24T00:00:00Z
P5875
P6179
1018181048